FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4316014279> ?p ?o ?g. }

• W4316014279 endingPage "1051" @default.
• W4316014279 startingPage "1045" @default.
• W4316014279 abstract "Background Epigenetic dysregulation is an integral step in the progression of pancreatic neuroendocrine tumors. We hypothesized that tumor suppressor repression by DNA methyltransferase 1 in pancreatic neuroendocrine tumors could be targeted with epigenetic treatment. Methods Resected pancreatic neuroendocrine tumors from 32 patients were stained for DNA methyltransferase 1 and scored. Human (BON1) and murine (STC) pancreatic neuroendocrine tumor cells were treated with DNA methyltransferase 1 inhibitor 5-azacytidine and chemotherapeutic agents 5-fluorouracil and temozolomide. Cell proliferation assay and tumor suppressor gene analysis were performed with qRT-PCR and Clarion S microarray. Tumor measurements were compared in a murine treatment model. Results High DNA methyltransferase scores were associated with high Ki-67 (6.7% vs 70.6% P < .01), mitotic rate (0.0% vs 31.3%), and grade (20.0% vs 80.4%, P < .01). Treatment with 5-azacytidine and chemotherapy resulted in a reduction of cell proliferation compared to chemotherapy alone in BON1 (77.3% vs 53.1%, P < .001) and STC (73.4% vs 34.2%, P < .001). Treatment with 5-azacytidine and chemotherapy resulted in upregulation of tumor suppressors CDKN1A (7.6 rel. fold, P < .001), BRCA2 (4.3 rel. fold, P < .001), and CDH1 (6.0 rel. fold, P = .026) in BON1 and CDKN1a (14.5 rel. fold, P < .001) and CDH (17.5 rel. fold, P < .001) in STC. In microarray, 5-azacytidine drove global genetic changes in combination treatment. In vivo tumors treated with chemotherapy measured 88.6 ± 19.54 mm3 vs 52.89 ± 10.51 mm3 in those treated with combination therapy (P = .009). Conclusion Epigenetic dysregulation with DNA methyltransferase 1 is associated with pancreatic neuroendocrine tumors and is a potential targetable strategy. 5-azacytidine and chemotherapy in combination can reduce cell proliferation, upregulate silenced tumor suppressor genes, and decrease in vivo tumors in pancreatic neuroendocrine tumors." @default.
• W4316014279 created "2023-01-14" @default.
• W4316014279 creator A5005657851 @default.
• W4316014279 creator A5014780308 @default.
• W4316014279 creator A5016850619 @default.
• W4316014279 creator A5018963635 @default.
• W4316014279 creator A5027336256 @default.
• W4316014279 creator A5052936772 @default.
• W4316014279 creator A5055151897 @default.
• W4316014279 creator A5056292669 @default.
• W4316014279 creator A5073292017 @default.
• W4316014279 creator A5074496503 @default.
• W4316014279 creator A5076483431 @default.
• W4316014279 creator A5079297340 @default.
• W4316014279 creator A5082730843 @default.
• W4316014279 creator A5085246647 @default.
• W4316014279 date "2023-04-01" @default.
• W4316014279 modified "2023-10-06" @default.
• W4316014279 title "Novel treatment strategy of targeting epigenetic dysregulation in pancreatic neuroendocrine tumors" @default.
• W4316014279 cites W1736033689 @default.
• W4316014279 cites W1972443124 @default.
• W4316014279 cites W1975143076 @default.
• W4316014279 cites W2036825872 @default.
• W4316014279 cites W2082472122 @default.
• W4316014279 cites W2153829642 @default.
• W4316014279 cites W2158247064 @default.
• W4316014279 cites W2160463900 @default.
• W4316014279 cites W2396364698 @default.
• W4316014279 cites W2400120669 @default.
• W4316014279 cites W2481985517 @default.
• W4316014279 cites W2597613988 @default.
• W4316014279 cites W2770293018 @default.
• W4316014279 cites W2782457553 @default.
• W4316014279 cites W2896748530 @default.
• W4316014279 cites W2915601865 @default.
• W4316014279 cites W2944761801 @default.
• W4316014279 cites W2986873684 @default.
• W4316014279 cites W2994934081 @default.
• W4316014279 cites W3009059686 @default.
• W4316014279 cites W3013041024 @default.
• W4316014279 cites W3153955088 @default.
• W4316014279 cites W4288715299 @default.
• W4316014279 doi "https://doi.org/10.1016/j.surg.2022.12.008" @default.
• W4316014279 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36642656" @default.
• W4316014279 hasPublicationYear "2023" @default.
• W4316014279 type Work @default.
• W4316014279 citedByCount "0" @default.
• W4316014279 crossrefType "journal-article" @default.
• W4316014279 hasAuthorship W4316014279A5005657851 @default.
• W4316014279 hasAuthorship W4316014279A5014780308 @default.
• W4316014279 hasAuthorship W4316014279A5016850619 @default.
• W4316014279 hasAuthorship W4316014279A5018963635 @default.
• W4316014279 hasAuthorship W4316014279A5027336256 @default.
• W4316014279 hasAuthorship W4316014279A5052936772 @default.
• W4316014279 hasAuthorship W4316014279A5055151897 @default.
• W4316014279 hasAuthorship W4316014279A5056292669 @default.
• W4316014279 hasAuthorship W4316014279A5073292017 @default.
• W4316014279 hasAuthorship W4316014279A5074496503 @default.
• W4316014279 hasAuthorship W4316014279A5076483431 @default.
• W4316014279 hasAuthorship W4316014279A5079297340 @default.
• W4316014279 hasAuthorship W4316014279A5082730843 @default.
• W4316014279 hasAuthorship W4316014279A5085246647 @default.
• W4316014279 hasConcept C104317684 @default.
• W4316014279 hasConcept C126322002 @default.
• W4316014279 hasConcept C143998085 @default.
• W4316014279 hasConcept C150194340 @default.
• W4316014279 hasConcept C190727270 @default.
• W4316014279 hasConcept C2776694085 @default.
• W4316014279 hasConcept C2777389519 @default.
• W4316014279 hasConcept C2779066768 @default.
• W4316014279 hasConcept C2779979206 @default.
• W4316014279 hasConcept C33288867 @default.
• W4316014279 hasConcept C41091548 @default.
• W4316014279 hasConcept C502942594 @default.
• W4316014279 hasConcept C54355233 @default.
• W4316014279 hasConcept C552990157 @default.
• W4316014279 hasConcept C55493867 @default.
• W4316014279 hasConcept C71924100 @default.
• W4316014279 hasConcept C86803240 @default.
• W4316014279 hasConcept C91965660 @default.
• W4316014279 hasConceptScore W4316014279C104317684 @default.
• W4316014279 hasConceptScore W4316014279C126322002 @default.
• W4316014279 hasConceptScore W4316014279C143998085 @default.
• W4316014279 hasConceptScore W4316014279C150194340 @default.
• W4316014279 hasConceptScore W4316014279C190727270 @default.
• W4316014279 hasConceptScore W4316014279C2776694085 @default.
• W4316014279 hasConceptScore W4316014279C2777389519 @default.
• W4316014279 hasConceptScore W4316014279C2779066768 @default.
• W4316014279 hasConceptScore W4316014279C2779979206 @default.
• W4316014279 hasConceptScore W4316014279C33288867 @default.
• W4316014279 hasConceptScore W4316014279C41091548 @default.
• W4316014279 hasConceptScore W4316014279C502942594 @default.
• W4316014279 hasConceptScore W4316014279C54355233 @default.
• W4316014279 hasConceptScore W4316014279C552990157 @default.
• W4316014279 hasConceptScore W4316014279C55493867 @default.
• W4316014279 hasConceptScore W4316014279C71924100 @default.
• W4316014279 hasConceptScore W4316014279C86803240 @default.
• W4316014279 hasConceptScore W4316014279C91965660 @default.

• next